Form 4 for COCH Envoy Medical, Inc.

Accepted 2026-02-17 00:00:00 ET · period of report 2026-02-12 · accession 0000914190-26-000024 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2026-02-17	2026-02-12	COCH	Lucas Brent T.	CEO, Dir	P - Purchase	$0.4	+62.5K	297.1K	+27%	+$25.0K
DM	2026-02-17	2026-02-12	COCH	Lucas Brent T.	CEO, Dir	P - Purchase	$0.00	+100.0K	62.5K	New	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Class A Common Stock	2026-02-12	P	A	62,500	$0.4	297,090	D	—	—
2	Derivative	Warrant (right to buy)	2026-02-12	P	A	37,500	$0.00	37,500	D	$0.4 · — to —	37,500 Class A Common Stock	(F4) Exercisable upon shareholder approval of the issuance of shares of Class A Common Stock underlying the warrants. (F5) The Series A-1 Warrants expire on the earlier of (i) two years from the initial exercise date and (ii) 30 days after the date on which the Company announces that it has submitted a Premarket Approval Application to the Food and Drug Administration (FDA) for its Acclaim CI Device.
3	Derivative	Warrant (right to buy)	2026-02-12	P	A	62,500	$0.00	62,500	D	$0.4 · — to —	62,500 Class A Common Stock	(F4) Exercisable upon shareholder approval of the issuance of shares of Class A Common Stock underlying the warrants. (F6) The Series A-2 Warrants expire on the earlier of (i) five years from the initial exercise date and (ii) 30 days after the date on which the Company announces that it has received FDA approval for its Acclaim CI Device.